The following content is part of a paid sponsorship and is not an endorsement by CHEST nor does it reflect the views or opinions of CHEST.
-
What are the signs of MACLD progression?
What are the signs of MACLD progression? Find out at SpotMACprogression.com. MAC=Mycobacterium avium complex; MACLD=MAC lung disease. NP-NTM-US-00302
-
Explore the dual pathways of IL-33
Join AstraZeneca at CHEST 2026 for a Learning Theater exploring the role of IL-33 in COPD. Learn how IL-33 may contribute to the pathogenesis of COPD, the role of reduced IL-33 (IL-33 RED) as a driver of inflammation, and how oxidized IL-33 (IL-33 OX) drives airway epithelial damage and mucus dysfunction. Don’t miss out on…
-
Behind the science: Considerations for severe asthma management
Join us for an engaging session exploring the evolving management of severe asthma, including the clinical evidence supporting a twice-yearly biologic, the impact of type 2 inflammation on disease progression, and persistent challenges in biologic use.
-
Learn More About AD109: An Investigational Oral Tablet for OSA
Visit Apnimed at Booth #1119 throughout CHEST 2026 to attend short expert-led scientific presentations, test your OSA IQ, engage with Medical Affairs colleagues, and learn about emerging research in obstructive sleep apnea (OSA).
-
Recognizing Bronchiectasis: When it might be more than COPD or asthma
Timely diagnosis is critical for patients with bronchiectasis, but many cases remain unrecognized. Please join bronchiectasis expert Dr. Colin Swenson as he examines clinical evidence to uncover a commonly missed driver of exacerbations and progressive lung function decline.
-
Panel perspectives on the evolving management of NCFB
Join experts Joseph Khabbaza, MD, of Cleveland, OH, Rajat Walia, MD, FCCP, of Phoenix, AZ, and Victoria Forth, PA-C, of Boston, MA, for an engaging discussion on the evolving management of non-cystic fibrosis bronchiectasis (NCFB). The discussion will focus on challenges in diagnosis, disease burden, and a treatment option for certain patients with NCFB.
-
Join Sanofi & Regeneron COPD Learning Theater at CHEST 2026
Please join us on Monday, October 19th from 10:15-11:00 a.m. MST in Learning Theater 2 at CHEST, where renowned pulmonologists Dr. Nicola Hanania and Dr. Diego Maselli will discuss the impact of exacerbations on disease progression, while underscoring the importance of COPD outcomes beyond exacerbation reduction. This medical theater will examine recent pooled Phase 3…
-
What are the signs of MACLD progression?
What are the signs of MACLD progression? Find out at SpotMACprogression.com. MAC=Mycobacterium avium complex; MACLD=MAC lung disease. NP-NTM-US-00302
-
Don’t miss the upcoming Learning Theater sponsored by Savara
Join Bruce C. Trapnell, MD, for an update on autoimmune pulmonary alveolar proteinosis (aPAP), covering the cardinal manifestations of the disease, burden of illness, and treatment landscape.
-
Precision Meets Protocol: Implementing Biomarkers Into a Structured Nodule Management Care Pathway
Join Dr. Sonali Sethi, board-certified Interventional Pulmonologist, for a practical discussion on how clinicians are incorporating biomarker-informed risk assessment into real-world lung nodule management.
-
Could AATD be hiding among your patients with COPD, uncontrolled asthma, or bronchiectasis?
Hear from patient Karen Erickson, who will share her experience with AATD, and Rajat Walia, MD, FCCP, an expert pulmonologist, as they discuss the realities of an AATD diagnostic journey and its implications for clinical practice.
-
Take Your Practice to the Next Level—Expert Guidance on Individualizing PAH Treatment and Bridging Guidelines to Real-World Care in MAC-LD
Join Answers in CME for two interactive live events designed to sharpen your clinical decision-making.
